Mind Pharmaceuticals

Website

Mind Pharmaceuticals Corp

1 Investors
Clinical Pharmaceuticals
NEW HAVEN, CT

Mind Pharmaceuticals is a Clinical Asset Stage Company located in New Haven, CT, dedicated to addressing significant unmet needs in the Central Nervous System (CNS) domain. The company's primary focus is on developing innovative treatments for Treatment Resistant Depression and Headache Disorders, responding to serious gaps in current mental health therapies.

Products & Team

MIND001

Psychedelic TherapySeed

MIND001 is an intravenous formulation of N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic compound. It targets receptors in the brain to potentially offer new therapeutic options for patients with Treatment Resistant Depression.

Value Proposition

MIND001 addresses the urgent need for effective treatments for patients suffering from Treatment Resistant Depression, who have not seen improvement with standard therapies.

Pain Points

Customers face persistent mental health challenges, with inadequate treatment options leading to significant life disruptions and poor quality of life.

Short-acting profileRapid onset of actionSustained efficacyGood safety and adverse event profileLow addictive potential
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
NEW HAVEN, CT
Primary headquarters

Funding History

Total Raised:
$50.0K
E

Equity, Debt Financing Offering

May 2025
$8.0M
Target
Progress
1%
Raised
$50.0K
Target
$8.0M
#000206822025000001